Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
Introduction There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the f...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2008-09, Vol.57 (9), p.1413-1420 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1420 |
|---|---|
| container_issue | 9 |
| container_start_page | 1413 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 57 |
| creator | Toubaji, Antoun Achtar, Moujahed Provenzano, Maurizio Herrin, Vincent E. Behrens, Robert Hamilton, Michael Bernstein, Sarah Venzon, David Gause, Barry Marincola, Francesco Khleif, Samir N. |
| description | Introduction
There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients.
Materials and methods
Twelve patients with no evidence of disease (NED), five pancreatic and seven colorectal cancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, corresponding to their tumor’s ras mutation. Vaccinations were given every 4 weeks, up to a total of six vaccines.
Results
No serious acute or delayed systemic side effects were seen. We detected specific immune responses to the relevant mutant ras peptide by measuring IFN-gamma mRNA expression by quantitative real-time PCR. Five out of eleven patients showed a positive immune response. Furthermore, the five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months. The seven colorectal cancer patients have shown a mean disease-free survival (DFS) of 27.2+ months and a mean overall survival (OS) of 41.5+ months.
Conclusion
In this study, we found that it is feasible to use mutant ras vaccine in the adjuvant setting. This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. Therefore, we believe that such an approach warrants further investigation in combination with other therapies. |
| doi_str_mv | 10.1007/s00262-008-0477-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69239629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-1edb65220cbc0d83d8c9c4ae451e01a7d97cc16c222f4df3d2e5ce51006290d3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqD_AiQXBvrZVKf55kWfyCBT3sPWQq1WuG7s6YdA_svzfNDLsqiKdUUk-9ValXiFcK3imA5n0CwBoLgLaAsmmK-onYqFLnl7ZST8UGdAlFA1CeifOUdjlA6Lrn4ky12DXYqo0Yv_shzDLNi7uXoZfjMttpltEmuef97B0XW5vYyYMl8hPLnLCTtG63HFZwjmznkXPkJ7m3E613T5lxksIQItNsB0k5wzG9EM96OyR-eTovxO2nj7fXX4qbb5-_Xl_dFFR11Vwodtu6QgTaErhWu5Y6Ki2XlWJQtnFdQ6RqQsS-dL12yBVxlXdSYwdOX4gPR9n9sh3ZUR4v2sHsox9tvDfBevNnZvI_zF04GKVAZw3MCpcnhRh-LpxmM_pEPAx24rAkU3eou9zsvyBCi1WJOoNv_gJ3YYlT3oJBpSvVqKbOkDpCFENKkfuHmRWY1XJztNxky81quVlrXv_-2ceKk8cZeHsCbCI79DF74dMDh1C2oOs2c3jkUk5NdxwfJ_x3919-G8VY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213517176</pqid></control><display><type>article</type><title>Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers</title><source>MEDLINE</source><source>PMC (PubMed Central)</source><source>SpringerLink Journals (MCLS)</source><creator>Toubaji, Antoun ; Achtar, Moujahed ; Provenzano, Maurizio ; Herrin, Vincent E. ; Behrens, Robert ; Hamilton, Michael ; Bernstein, Sarah ; Venzon, David ; Gause, Barry ; Marincola, Francesco ; Khleif, Samir N.</creator><creatorcontrib>Toubaji, Antoun ; Achtar, Moujahed ; Provenzano, Maurizio ; Herrin, Vincent E. ; Behrens, Robert ; Hamilton, Michael ; Bernstein, Sarah ; Venzon, David ; Gause, Barry ; Marincola, Francesco ; Khleif, Samir N.</creatorcontrib><description>Introduction
There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients.
Materials and methods
Twelve patients with no evidence of disease (NED), five pancreatic and seven colorectal cancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, corresponding to their tumor’s ras mutation. Vaccinations were given every 4 weeks, up to a total of six vaccines.
Results
No serious acute or delayed systemic side effects were seen. We detected specific immune responses to the relevant mutant ras peptide by measuring IFN-gamma mRNA expression by quantitative real-time PCR. Five out of eleven patients showed a positive immune response. Furthermore, the five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months. The seven colorectal cancer patients have shown a mean disease-free survival (DFS) of 27.2+ months and a mean overall survival (OS) of 41.5+ months.
Conclusion
In this study, we found that it is feasible to use mutant ras vaccine in the adjuvant setting. This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. Therefore, we believe that such an approach warrants further investigation in combination with other therapies.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-008-0477-6</identifier><identifier>PMID: 18297281</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Cancer Research ; Cancer Vaccines - chemistry ; Cancer Vaccines - therapeutic use ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - therapy ; Disease-Free Survival ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Genes, ras ; Humans ; Immunology ; Immunotherapy ; Immunotherapy - methods ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Original ; Original Article ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - therapy ; Pharmacology. Drug treatments ; Pilot Projects ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2008-09, Vol.57 (9), p.1413-1420</ispartof><rights>Springer-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-1edb65220cbc0d83d8c9c4ae451e01a7d97cc16c222f4df3d2e5ce51006290d3</citedby><cites>FETCH-LOGICAL-c595t-1edb65220cbc0d83d8c9c4ae451e01a7d97cc16c222f4df3d2e5ce51006290d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030622/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030622/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20480368$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18297281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toubaji, Antoun</creatorcontrib><creatorcontrib>Achtar, Moujahed</creatorcontrib><creatorcontrib>Provenzano, Maurizio</creatorcontrib><creatorcontrib>Herrin, Vincent E.</creatorcontrib><creatorcontrib>Behrens, Robert</creatorcontrib><creatorcontrib>Hamilton, Michael</creatorcontrib><creatorcontrib>Bernstein, Sarah</creatorcontrib><creatorcontrib>Venzon, David</creatorcontrib><creatorcontrib>Gause, Barry</creatorcontrib><creatorcontrib>Marincola, Francesco</creatorcontrib><creatorcontrib>Khleif, Samir N.</creatorcontrib><title>Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Introduction
There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients.
Materials and methods
Twelve patients with no evidence of disease (NED), five pancreatic and seven colorectal cancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, corresponding to their tumor’s ras mutation. Vaccinations were given every 4 weeks, up to a total of six vaccines.
Results
No serious acute or delayed systemic side effects were seen. We detected specific immune responses to the relevant mutant ras peptide by measuring IFN-gamma mRNA expression by quantitative real-time PCR. Five out of eleven patients showed a positive immune response. Furthermore, the five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months. The seven colorectal cancer patients have shown a mean disease-free survival (DFS) of 27.2+ months and a mean overall survival (OS) of 41.5+ months.
Conclusion
In this study, we found that it is feasible to use mutant ras vaccine in the adjuvant setting. This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. Therefore, we believe that such an approach warrants further investigation in combination with other therapies.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cancer Vaccines - chemistry</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genes, ras</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU2LFDEQhoMo7uzqD_AiQXBvrZVKf55kWfyCBT3sPWQq1WuG7s6YdA_svzfNDLsqiKdUUk-9ValXiFcK3imA5n0CwBoLgLaAsmmK-onYqFLnl7ZST8UGdAlFA1CeifOUdjlA6Lrn4ky12DXYqo0Yv_shzDLNi7uXoZfjMttpltEmuef97B0XW5vYyYMl8hPLnLCTtG63HFZwjmznkXPkJ7m3E613T5lxksIQItNsB0k5wzG9EM96OyR-eTovxO2nj7fXX4qbb5-_Xl_dFFR11Vwodtu6QgTaErhWu5Y6Ki2XlWJQtnFdQ6RqQsS-dL12yBVxlXdSYwdOX4gPR9n9sh3ZUR4v2sHsox9tvDfBevNnZvI_zF04GKVAZw3MCpcnhRh-LpxmM_pEPAx24rAkU3eou9zsvyBCi1WJOoNv_gJ3YYlT3oJBpSvVqKbOkDpCFENKkfuHmRWY1XJztNxky81quVlrXv_-2ceKk8cZeHsCbCI79DF74dMDh1C2oOs2c3jkUk5NdxwfJ_x3919-G8VY</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Toubaji, Antoun</creator><creator>Achtar, Moujahed</creator><creator>Provenzano, Maurizio</creator><creator>Herrin, Vincent E.</creator><creator>Behrens, Robert</creator><creator>Hamilton, Michael</creator><creator>Bernstein, Sarah</creator><creator>Venzon, David</creator><creator>Gause, Barry</creator><creator>Marincola, Francesco</creator><creator>Khleif, Samir N.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080901</creationdate><title>Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers</title><author>Toubaji, Antoun ; Achtar, Moujahed ; Provenzano, Maurizio ; Herrin, Vincent E. ; Behrens, Robert ; Hamilton, Michael ; Bernstein, Sarah ; Venzon, David ; Gause, Barry ; Marincola, Francesco ; Khleif, Samir N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-1edb65220cbc0d83d8c9c4ae451e01a7d97cc16c222f4df3d2e5ce51006290d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cancer Vaccines - chemistry</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genes, ras</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toubaji, Antoun</creatorcontrib><creatorcontrib>Achtar, Moujahed</creatorcontrib><creatorcontrib>Provenzano, Maurizio</creatorcontrib><creatorcontrib>Herrin, Vincent E.</creatorcontrib><creatorcontrib>Behrens, Robert</creatorcontrib><creatorcontrib>Hamilton, Michael</creatorcontrib><creatorcontrib>Bernstein, Sarah</creatorcontrib><creatorcontrib>Venzon, David</creatorcontrib><creatorcontrib>Gause, Barry</creatorcontrib><creatorcontrib>Marincola, Francesco</creatorcontrib><creatorcontrib>Khleif, Samir N.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toubaji, Antoun</au><au>Achtar, Moujahed</au><au>Provenzano, Maurizio</au><au>Herrin, Vincent E.</au><au>Behrens, Robert</au><au>Hamilton, Michael</au><au>Bernstein, Sarah</au><au>Venzon, David</au><au>Gause, Barry</au><au>Marincola, Francesco</au><au>Khleif, Samir N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>57</volume><issue>9</issue><spage>1413</spage><epage>1420</epage><pages>1413-1420</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>Introduction
There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients.
Materials and methods
Twelve patients with no evidence of disease (NED), five pancreatic and seven colorectal cancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, corresponding to their tumor’s ras mutation. Vaccinations were given every 4 weeks, up to a total of six vaccines.
Results
No serious acute or delayed systemic side effects were seen. We detected specific immune responses to the relevant mutant ras peptide by measuring IFN-gamma mRNA expression by quantitative real-time PCR. Five out of eleven patients showed a positive immune response. Furthermore, the five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months. The seven colorectal cancer patients have shown a mean disease-free survival (DFS) of 27.2+ months and a mean overall survival (OS) of 41.5+ months.
Conclusion
In this study, we found that it is feasible to use mutant ras vaccine in the adjuvant setting. This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. Therefore, we believe that such an approach warrants further investigation in combination with other therapies.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18297281</pmid><doi>10.1007/s00262-008-0477-6</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2008-09, Vol.57 (9), p.1413-1420 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030622 |
| source | MEDLINE; PMC (PubMed Central); SpringerLink Journals (MCLS) |
| subjects | Adjuvants, Immunologic - therapeutic use Adult Aged Antineoplastic agents Biological and medical sciences Cancer Research Cancer Vaccines - chemistry Cancer Vaccines - therapeutic use Colorectal Neoplasms - genetics Colorectal Neoplasms - therapy Disease-Free Survival Female Gastroenterology. Liver. Pancreas. Abdomen Genes, ras Humans Immunology Immunotherapy Immunotherapy - methods Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Medicine Medicine & Public Health Middle Aged Mutation Oncology Original Original Article Pancreatic Neoplasms - genetics Pancreatic Neoplasms - therapy Pharmacology. Drug treatments Pilot Projects Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T18%3A47%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20study%20of%20mutant%20ras%20peptide-based%20vaccine%20as%20an%20adjuvant%20treatment%20in%20pancreatic%20and%20colorectal%20cancers&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Toubaji,%20Antoun&rft.date=2008-09-01&rft.volume=57&rft.issue=9&rft.spage=1413&rft.epage=1420&rft.pages=1413-1420&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s00262-008-0477-6&rft_dat=%3Cproquest_pubme%3E69239629%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213517176&rft_id=info:pmid/18297281&rfr_iscdi=true |